Medicare may have released a plan to restrict access to the controversial Biogen Alzheimer’s drug, but the biggest losers may actually be other drug makers readying treatments for the debilitating disease.
The question is whether they encounter such difficulties and, if so, to what extent?
Create a display name to comment
This name will appear with your comment
